HealthEquity (NASDAQ:HQY) Posts Earnings Results, Beats Estimates By $0.05 EPS

HealthEquity (NASDAQ:HQY) released its earnings results on Tuesday. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.05, FiscalAI reports. HealthEquity had a net margin of 16.39% and a return on equity of 13.82%. The company had revenue of $334.59 million during the quarter, compared to analyst estimates of $332.48 million. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year.

Here are the key takeaways from HealthEquity’s conference call:

• Strong fiscal‑2026 execution: Q4 adjusted EBITDA grew 23% with >500 bps margin expansion, the company added >1 million HSAs from sales in FY26 (total 17.8M accounts) and HSA assets topped $36B while returning $300M+ to shareholders via repurchases.
• Gross margin expansion was driven by sharply reduced fraud costs (Q4 fraud reimbursements ≈ $0.3M, exit run‑rate ~0.1 bps) and lower service costs, and management expects AI and automation to further lower cost‑to‑serve and boost operating leverage.
• Regulatory tailwind and new distribution: expansion of HSA eligibility to ACA Bronze plans creates roughly a ~10% market expansion, and HealthEquity launched direct retail enrollment to capture exchange consumers.
• Early‑stage Marketplace rollout (weight‑loss programs including GLP‑1, HRT, wearables) shows encouraging initial retention and engagement but is not yet a material contributor to guidance; management sees it as a future avenue for recurring revenue and higher engagement.

HealthEquity Trading Up 0.2%

Shares of HQY opened at $79.57 on Thursday. The firm has a market cap of $6.80 billion, a P/E ratio of 32.35, a price-to-earnings-growth ratio of 0.99 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.13 and a quick ratio of 4.13. HealthEquity has a 1 year low of $72.76 and a 1 year high of $116.65. The company has a 50 day simple moving average of $80.93 and a two-hundred day simple moving average of $90.20.

Key Headlines Impacting HealthEquity

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: Q4 beat and raised guidance — HealthEquity reported record revenue and earnings (Q4 EPS $0.95 vs. $0.90 consensus; revenue $334.6M vs. $332.5M consensus), with FY26 net income +123% to $215.2M and management raising fiscal 2027 outlook. This is the main catalyst supporting the stock move. Read More.
• Positive Sentiment: Analyst upgrade/rehab — Seeking Alpha published a rating upgrade noting improved cash economics, reinforcing the bullish view driven by better margins and cash conversion. This supports continued positive sentiment from investors. Read More.
• Neutral Sentiment: Detailed call/transcript available — Investors can review the earnings call and transcripts for color on HSA growth, expense cadence, and margin drivers; these details will shape how durable the guidance raise is. Read More.
• Negative Sentiment: Barrington cut its price target from $125 to $110 (still Outperform) — target cut reduces one measure of upside even though the rating remains positive. Read More.
• Negative Sentiment: JPMorgan trimmed its target from $129 to $123 (still Overweight) — another target reduction that could temper investor enthusiasm despite the overweight rating. Read More. Read More.
• Negative Sentiment: RBC lowered its target from $110 to $100 (still Outperform) — similar theme: analysts kept favorable ratings but reduced upside targets, which may cap short-term gains. Read More.

Analyst Upgrades and Downgrades

HQY has been the subject of a number of recent analyst reports. Citigroup reiterated an “outperform” rating on shares of HealthEquity in a research report on Thursday, December 4th. Jefferies Financial Group set a $108.00 price objective on shares of HealthEquity in a research report on Thursday, February 19th. Barrington Research lowered their target price on shares of HealthEquity from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Wednesday. Raymond James Financial set a $100.00 price target on HealthEquity in a research note on Tuesday, February 17th. Finally, JPMorgan Chase & Co. decreased their price target on HealthEquity from $129.00 to $123.00 and set an “overweight” rating on the stock in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $109.79.

Insider Activity at HealthEquity

In related news, EVP Delano Ladd sold 1,500 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $94.72, for a total transaction of $142,080.00. Following the completion of the transaction, the executive vice president owned 73,979 shares in the company, valued at approximately $7,007,290.88. This represents a 1.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.50% of the company’s stock.

Institutional Trading of HealthEquity

Several hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC grew its holdings in HealthEquity by 148.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,107,448 shares of the company’s stock valued at $116,016,000 after buying an additional 661,795 shares in the last quarter. Millennium Management LLC raised its holdings in shares of HealthEquity by 151.5% during the 4th quarter. Millennium Management LLC now owns 951,563 shares of the company’s stock worth $87,173,000 after acquiring an additional 573,283 shares in the last quarter. Cadian Capital Management LP purchased a new stake in shares of HealthEquity during the 4th quarter worth approximately $51,915,000. Wasatch Advisors LP boosted its position in shares of HealthEquity by 4.5% during the 4th quarter. Wasatch Advisors LP now owns 6,589,646 shares of the company’s stock valued at $603,677,000 after acquiring an additional 281,971 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of HealthEquity during the 4th quarter valued at approximately $25,800,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.